Ten-day Sequential Therapy versus Bismuth Based Quadruple Therapy as Second Line Treatment for Helicobacter pylori Infection.
10.4166/kjg.2015.66.5.261
- Author:
Sung Bum KIM
1
;
Si Hyung LEE
;
Kyeong Ok KIM
;
Byung Ik JANG
;
Tae Nyeun KIM
Author Information
1. Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea. dr9696@nate.com
- Publication Type:Original Article
- Keywords:
Helicobacter pylori;
Eradication;
Anti-bacterial agents
- MeSH:
Adult;
Aged;
Aged, 80 and over;
Anti-Bacterial Agents/adverse effects/pharmacology/*therapeutic use;
Bismuth/adverse effects/pharmacology/*therapeutic use;
Diarrhea/etiology;
Drug Administration Schedule;
Drug Therapy, Combination;
Female;
Helicobacter Infections/*drug therapy;
Helicobacter pylori/drug effects;
Humans;
Male;
Middle Aged;
Proton Pump Inhibitors/adverse effects/pharmacology/therapeutic use;
Retrospective Studies;
Risk Factors;
Taste Disorders/etiology;
Treatment Outcome;
Young Adult
- From:The Korean Journal of Gastroenterology
2015;66(5):261-267
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND/AIMS: Ten-day sequential therapy has been evaluated as the first line therapy for Helicobacter pylori eradication but studies on sequential therapy as a second line therapy is lacking. The aim of this study was to compare the efficacy of 10-day sequential therapy and quadruple therapy as second line treatment for H. pylori eradication after failure of standard triple therapy. METHODS: Patients who did not respond to standard triple therapy for H. pylori eradication were assigned to either 10-day sequential or bismuth based quadruple therapy as second line treatment from January 2009 to December 2014 at Yeungnam University Medical Center. Post treatment H. pylori status was determined by rapid urease test, giemsa staining, or 13C-urea breath test. Eradication rate and side effects of both therapies were compared. RESULTS: A total of 158 H. pylori infected patients were included and 70 patients were treated by bismuth based quadruple therapy and 88 patients by 10-day sequential therapy. Age and sex were not significantly different between the two groups. Eradication rate was 84.3% (59/70) in quadruple group and 56.8% (50/88) in sequential group. Side effects occurred significantly higher in quadruple group than sequential group (27.1% vs. 11.4%, p=0.011). CONCLUSIONS: For second line H. pylori eradication after failure of standard triple therapy, bismuth based quadruple therapy showed significantly higher H. pylori eradication rate than 10-day sequential therapy. Further prospective studies are needed to evaluate the efficacy of 10-day sequential therapy as a second line H. pylori eradication treatment.
